| Rx0000101 |
Par Pharmaceutical |
12/31/2019 |
42023010301 |
Adrenalin, Nasal Solution 0.1%, 30 mL, Bottle |
11/13/2019 |
41.76 |
250.57 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Par believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 1/17/2020, the Orange Book database does not contain unexpired patents for this product. As a result, Par has left the patent expiration date field for this product blank. (3) Par did not acquire this product from another manufacturer within the previous five years (i.e., sixty months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000101 |
Par Pharmaceutical |
06/30/2019 |
42023017905 |
Buprenorphine HCl, Injection 0.3 mg/mL 5vl |
05/08/2019 |
8.88 |
68.10 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 8/2/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer. As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000209 |
Parsolex GMP Center, Inc. |
03/31/2019 |
13845120202 |
CycloSERINE Capsules, USP 250 mg, 30 capsules per blister pack |
02/07/2019 |
274.00 |
2090.00 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Parsolex is a privately held corporation and, pursuant to applicable law and regulation, has limited the information submitted herein to that which is otherwise in the public domain or publicly available. Parsolex has accordingly marked the “Unit Sales Volume US” and “Cost Increase Factors” fields as non-public. Parsolex has left the “Patent Expiration Date” field blank, because there is none. Parsolex also has left columns 14 through 22 intentionally blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069046856 |
Chantix, 0.5 mg Tablet, 56's |
01/15/2019 |
20.06 |
421.31 |
08/03/2022 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069046956 |
Chantix, 1 mg Tablet, 56's |
01/15/2019 |
20.06 |
421.31 |
08/03/2022 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069046903 |
Chantix, Continuing Month Box - 1 mg Tablet (4 Continuing weeks), (1x56) |
01/15/2019 |
20.06 |
421.31 |
08/03/2022 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069047103 |
Chantix, Starting Month Box - 0.5 mg Tablet (1 Starting Week) & 1 mg Tablet (3 Continuing Weeks), (1x11) & 3 (1x42) |
01/15/2019 |
20.06 |
421.31 |
08/03/2022 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071036940 |
Dilantin, 100 mg Capsule Unit Dose Pak, (10x10) |
01/15/2019 |
6.82 |
143.16 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071036932 |
Dilantin, 100 mg Capsule, 1000's |
01/15/2019 |
61.78 |
1297.29 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071036924 |
Dilantin, 100 mg Capsule, 100's |
01/15/2019 |
6.18 |
129.73 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071374066 |
Dilantin, 30 mg Capsule, 100's |
01/15/2019 |
5.33 |
111.86 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071000740 |
Dilantin, 50 mg Infatabs Unit Dose Pak, (10x10) |
01/15/2019 |
8.21 |
172.41 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071000724 |
Dilantin, 50 mg Infatabs, 100's |
01/15/2019 |
5.79 |
121.56 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071221420 |
Dilantin-125, 125 mg/5 mL Bottle, 8 oz |
01/15/2019 |
7.70 |
161.69 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008083621 |
Effexor XR, 150 mg Capsule Extended Release, 30's |
01/15/2019 |
22.99 |
482.88 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008083622 |
Effexor XR, 150 mg Capsule Extended Release, 90's |
01/15/2019 |
68.99 |
1448.73 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008083721 |
Effexor XR, 37.5 mg Capsule Extended Release, 30's |
01/15/2019 |
18.84 |
395.65 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008083722 |
Effexor XR, 37.5 mg Capsule Extended Release, 90's |
01/15/2019 |
56.53 |
1187.03 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008083321 |
Effexor XR, 75 mg Capsule Extended Release, 15's |
01/15/2019 |
21.11 |
443.31 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008083322 |
Effexor XR, 75 mg Capsule Extended Release, 90's |
01/15/2019 |
63.34 |
1330.04 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00013215036 |
Estring, 2 mg Ring, 1's |
01/15/2019 |
21.57 |
452.91 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085410 |
Levoxyl, 100 mcg (0.1 mg) Tablet, 1000's |
01/15/2019 |
42.64 |
895.34 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085401 |
Levoxyl, 100 mcg (0.1 mg) Tablet, 100's |
01/15/2019 |
4.26 |
89.54 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085510 |
Levoxyl, 112 mcg (0.112 mg) Tablet, 1000's |
01/15/2019 |
49.30 |
1035.35 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085501 |
Levoxyl, 112 mcg (0.112 mg) Tablet, 100's |
01/15/2019 |
4.93 |
103.54 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085610 |
Levoxyl, 125 mcg (0.125 mg) Tablet, 1000's |
01/15/2019 |
49.99 |
1049.72 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085601 |
Levoxyl, 125 mcg (0.125 mg) Tablet, 100's |
01/15/2019 |
5.00 |
104.96 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085710 |
Levoxyl, 137 mcg (0.137 mg) Tablet, 1000's |
01/15/2019 |
50.68 |
1064.29 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085701 |
Levoxyl, 137 mcg (0.137 mg) Tablet, 100's |
01/15/2019 |
5.07 |
106.42 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085810 |
Levoxyl, 150 mcg (0.15 mg) Tablet, 1000's |
01/15/2019 |
51.45 |
1080.42 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085801 |
Levoxyl, 150 mcg (0.15 mg) Tablet, 100's |
01/15/2019 |
5.15 |
108.05 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085910 |
Levoxyl, 175 mcg (0.175 mg) Tablet, 1000's |
01/15/2019 |
61.15 |
1284.08 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085901 |
Levoxyl, 175 mcg (0.175 mg) Tablet, 100's |
01/15/2019 |
6.12 |
128.42 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793086010 |
Levoxyl, 200 mcg (0.2 mg) Tablet, 1000's |
01/15/2019 |
61.27 |
1286.66 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793086001 |
Levoxyl, 200 mcg (0.2 mg) Tablet, 100's |
01/15/2019 |
6.13 |
128.66 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085010 |
Levoxyl, 25 mcg (0.025 mg) Tablet, 1000's |
01/15/2019 |
33.16 |
696.29 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085001 |
Levoxyl, 25 mcg (0.025 mg) Tablet, 100's |
01/15/2019 |
3.32 |
69.62 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085110 |
Levoxyl, 50 mcg (0.05 mg) Tablet, 1000's |
01/15/2019 |
37.64 |
790.40 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085101 |
Levoxyl, 50 mcg (0.05 mg) Tablet, 100's |
01/15/2019 |
3.76 |
79.03 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085210 |
Levoxyl, 75 mcg (0.075 mg) Tablet, 1000's |
01/15/2019 |
41.59 |
873.47 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085201 |
Levoxyl, 75 mcg (0.075 mg) Tablet, 100's |
01/15/2019 |
4.16 |
87.35 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085310 |
Levoxyl, 88 mcg (0.088 mg) Tablet, 1000's |
01/15/2019 |
42.31 |
888.52 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
60793085301 |
Levoxyl, 88 mcg (0.088 mg) Tablet, 100's |
01/15/2019 |
4.23 |
88.85 |
10/02/2023 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071015540 |
Lipitor, 10 mg Tablet Unit Dose Pak, 10x10 |
01/15/2019 |
52.40 |
1100.35 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071015523 |
Lipitor, 10 mg Tablet, 90's |
01/15/2019 |
44.91 |
943.18 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071015640 |
Lipitor, 20 mg Tablet Unit Dose Pak, 10x10 |
01/15/2019 |
74.75 |
1569.69 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071015623 |
Lipitor, 20 mg Tablet, 90's |
01/15/2019 |
64.07 |
1345.42 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071015740 |
Lipitor, 40 mg Tablet Unit Dose Pak, 10x10 |
01/15/2019 |
74.75 |
1569.69 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071015773 |
Lipitor, 40 mg Tablet, 500's |
01/15/2019 |
355.92 |
7474.39 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071015723 |
Lipitor, 40 mg Tablet, 90's |
01/15/2019 |
64.07 |
1345.42 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071015892 |
Lipitor, 80 mg Tablet Unit Dose Pak, 8x8 |
01/15/2019 |
47.84 |
1004.60 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071015873 |
Lipitor, 80 mg Tablet, 500's |
01/15/2019 |
355.92 |
7474.39 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071015823 |
Lipitor, 80 mg Tablet, 90's |
01/15/2019 |
64.07 |
1345.42 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071101541 |
Lyrica, 100 mg Capsule Unit Dose Pak, 10x10 |
01/15/2019 |
40.87 |
858.26 |
06/30/2019 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071101568 |
Lyrica, 100 mg Capsule, 90's |
01/15/2019 |
33.44 |
702.28 |
06/30/2019 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071101641 |
Lyrica, 150 mg Capsule Unit Dose Pak, 10x10 |
01/15/2019 |
40.87 |
858.26 |
06/30/2019 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071101668 |
Lyrica, 150 mg Capsule, 90's |
01/15/2019 |
33.44 |
702.28 |
06/30/2019 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071102001 |
Lyrica, 20 mg/mL Bottle, 1's |
01/15/2019 |
46.82 |
983.20 |
06/30/2019 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071101768 |
Lyrica, 200 mg Capsule, 90's |
01/15/2019 |
33.44 |
702.28 |
06/30/2019 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071101968 |
Lyrica, 225 mg Capsule, 90's |
01/15/2019 |
33.44 |
702.28 |
06/30/2019 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071101268 |
Lyrica, 25 mg Capsule, 90's |
01/15/2019 |
33.44 |
702.28 |
06/30/2019 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071101868 |
Lyrica, 300 mg Capsule, 90's |
01/15/2019 |
33.44 |
702.28 |
06/30/2019 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071101341 |
Lyrica, 50 mg Capsule Unit Dose Pak, 10x10 |
01/15/2019 |
40.87 |
858.26 |
06/30/2019 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071101368 |
Lyrica, 50 mg Capsule, 90's |
01/15/2019 |
33.44 |
702.28 |
06/30/2019 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071101441 |
Lyrica, 75 mg Capsule Unit Dose Pak, 10x10 |
01/15/2019 |
40.87 |
858.26 |
06/30/2019 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071101468 |
Lyrica, 75 mg Capsule, 90's |
01/15/2019 |
33.44 |
702.28 |
06/30/2019 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008451001 |
Mylotarg, 4.5 mg Single Dose Vial, 1's |
01/15/2019 |
246.00 |
8446.00 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=240 |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071080324 |
Neurontin, 100 mg Capsule, 100's |
01/15/2019 |
10.63 |
223.17 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071080524 |
Neurontin, 300 mg Capsule, 100's |
01/15/2019 |
26.57 |
558.01 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071080624 |
Neurontin, 400 mg Capsule, 100's |
01/15/2019 |
31.88 |
669.42 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071051324 |
Neurontin, 600 mg Tablet, 100's |
01/15/2019 |
50.48 |
1060.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00071040124 |
Neurontin, 800 mg Tablet, 100's |
01/15/2019 |
60.56 |
1271.83 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069154041 |
Norvasc, 10 mg Tablet Unit Dose Pak, (10x10) |
01/15/2019 |
42.67 |
896.01 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069154068 |
Norvasc, 10 mg Tablet, 90's |
01/15/2019 |
38.38 |
806.01 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069152068 |
Norvasc, 2.5 mg Tablet, 90's |
01/15/2019 |
28.00 |
587.90 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069153041 |
Norvasc, 5 mg Tablet Unit Dose Pak, (10x10) |
01/15/2019 |
31.10 |
653.19 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069153072 |
Norvasc, 5 mg Tablet, 300's |
01/15/2019 |
93.32 |
1959.68 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069153068 |
Norvasc, 5 mg Tablet, 90's |
01/15/2019 |
28.00 |
587.90 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008122214 |
Pristiq, 100 mg Tablet Extended Release, 14's |
01/15/2019 |
8.91 |
187.03 |
07/05/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008122230 |
Pristiq, 100 mg Tablet Extended Release, 30's |
01/15/2019 |
19.09 |
400.81 |
07/05/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008122201 |
Pristiq, 100 mg Tablet Extended Release, 90's |
01/15/2019 |
57.26 |
1202.37 |
07/05/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008121030 |
Pristiq, 25 mg Tablet Extended Release, 30's |
01/15/2019 |
19.09 |
400.81 |
07/05/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008121114 |
Pristiq, 50 mg Tablet Extended Release, 14's |
01/15/2019 |
8.91 |
187.03 |
07/05/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008121130 |
Pristiq, 50 mg Tablet Extended Release, 30's |
01/15/2019 |
19.09 |
400.81 |
07/05/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008121101 |
Pristiq, 50 mg Tablet Extended Release, 90's |
01/15/2019 |
57.26 |
1202.37 |
07/05/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008084381 |
Protonix, 20 mg Tablet Delayed Release, 90's |
01/15/2019 |
64.57 |
1355.89 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008084402 |
Protonix, 40 mg Packet, 30's |
01/15/2019 |
21.52 |
451.94 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008084181 |
Protonix, 40 mg Tablet Delayed Release, 90's |
01/15/2019 |
64.57 |
1355.89 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008104010 |
Rapamune, 0.5 mg Tablet Redipak, 10x10 |
01/15/2019 |
73.10 |
1535.15 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008104005 |
Rapamune, 0.5 mg Tablet, 100's |
01/15/2019 |
73.10 |
1535.15 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008104110 |
Rapamune, 1 mg Tablet Redipak, 10x10 |
01/15/2019 |
146.20 |
3070.11 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008104105 |
Rapamune, 1 mg Tablet, 100's |
01/15/2019 |
146.20 |
3070.11 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00008104205 |
Rapamune, 2 mg Tablet, 100's |
01/15/2019 |
292.39 |
6140.18 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00009716601 |
Somavert, 10 mg/8 mL Syringe, 1's |
01/15/2019 |
10.30 |
216.33 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00009716801 |
Somavert, 15 mg/8 mL Syringe, 1's |
01/15/2019 |
15.45 |
324.51 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00009718801 |
Somavert, 20 mg/8 mL Syringe, 1's |
01/15/2019 |
20.60 |
432.66 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00009719901 |
Somavert, 25 mg/8 mL Syringe, 1's |
01/15/2019 |
25.75 |
540.83 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00009720001 |
Somavert, 30 mg/8 mL Syringe, 1's |
01/15/2019 |
30.90 |
648.99 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069024230 |
Toviaz, 4 mg Tablet Extended Release, 30's |
01/15/2019 |
15.79 |
331.59 |
06/07/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069024430 |
Toviaz, 8 mg Tablet Extended Release, 30's |
01/15/2019 |
15.79 |
331.59 |
06/07/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069422033 |
Viagra, 100 mg Tablet Single Pack, 1x30 |
01/15/2019 |
101.03 |
2121.53 |
10/22/2019 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069422066 |
Viagra, 100 mg Tablet, 100's |
01/15/2019 |
336.74 |
7071.56 |
10/22/2019 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069422030 |
Viagra, 100 mg Tablet, 30's |
01/15/2019 |
101.03 |
2121.53 |
10/22/2019 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069420030 |
Viagra, 25 mg Tablet, 30's |
01/15/2019 |
101.03 |
2121.53 |
10/22/2019 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069421033 |
Viagra, 50 mg Tablet Single Pack, 1x30 |
01/15/2019 |
101.03 |
2121.53 |
10/22/2019 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069421066 |
Viagra, 50 mg Tablet, 100's |
01/15/2019 |
336.74 |
7071.56 |
10/22/2019 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069421030 |
Viagra, 50 mg Tablet, 30's |
01/15/2019 |
101.03 |
2121.53 |
10/22/2019 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00009002901 |
Xanax, 0.25 mg Tablet, 100's |
01/15/2019 |
20.00 |
420.08 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00009002902 |
Xanax, 0.25 mg Tablet, 500's |
01/15/2019 |
100.02 |
2100.36 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00009005501 |
Xanax, 0.5 mg Tablet, 100's |
01/15/2019 |
24.92 |
523.34 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00009005503 |
Xanax, 0.5 mg Tablet, 500's |
01/15/2019 |
124.61 |
2616.73 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00009009001 |
Xanax, 1 mg Tablet, 100's |
01/15/2019 |
33.25 |
698.32 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00009009004 |
Xanax, 1 mg Tablet, 500's |
01/15/2019 |
166.27 |
3491.57 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00009009401 |
Xanax, 2 mg Tablet, 100's |
01/15/2019 |
56.54 |
1187.32 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069050130 |
Xeljanz, 11 mg Tablet, 1x30 |
01/15/2019 |
384.99 |
4480.63 |
12/08/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00069100101 |
Xeljanz, 5 mg Tablet, 60's |
01/15/2019 |
384.99 |
4480.63 |
12/08/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00049491041 |
Zoloft, 100 mg Tablet Unit Dose Pak, (10x10) |
01/15/2019 |
53.11 |
1115.23 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00049491030 |
Zoloft, 100 mg Tablet, 30's |
01/15/2019 |
15.93 |
334.55 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00049496030 |
Zoloft, 25 mg Tablet, 30's |
01/15/2019 |
15.93 |
334.55 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00049490041 |
Zoloft, 50 mg Tablet Unit Dose Pak, (10x10) |
01/15/2019 |
53.11 |
1115.23 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2019 |
00049490030 |
Zoloft, 50 mg Tablet, 30's |
01/15/2019 |
15.93 |
334.55 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity.
(3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2019 |
00121154440 |
Hydrocodone / Apap Oral Solution 5/217mg/10mL 10mL |
02/01/2019 |
59.84 |
327.21 |
None |
Non-innovator Multiple Source Drug |
995 |
None |
to remain competitive as determined by our pricing committee |
None |
No change or Improvement to product. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Per email where the listed WAC price change dates do not match Medi-Span price change dates. The dates listed in this report are the dates that the WAC price was changed in our ERP system and customers were charged the new WAC price.
The drug was not acquired so the acquisition related fields are empty. |
| Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2019 |
00121231640 |
Hydrocodone /Apap Oral Solution 7.5/217mg/15mL 15mL |
02/01/2019 |
168.33 |
330.88 |
None |
Non-innovator Multiple Source Drug |
2410 |
None |
to remain competitive as determined by our pricing committee |
None |
No change or Improvement to product. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Per email where the listed WAC price change dates do not match Medi-Span price change dates. The dates listed in this report are the dates that the WAC price was changed in our ERP system and customers were charged the new WAC price.
The drug was not acquired so the acquisition related fields are empty. |
| Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2019 |
00121059500 |
Sodium Citrate and Citric Acid Oral Solution 1500/1002mg 15 mL |
02/01/2019 |
69.05 |
297.70 |
None |
Non-innovator Multiple Source Drug |
1687 |
None |
to remain competitive as determined by our pricing committee |
None |
No change or Improvement to product. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Per email where the listed WAC price change dates do not match Medi-Span price change dates. The dates listed in this report are the dates that the WAC price was changed in our ERP system and customers were charged the new WAC price.
The drug was not acquired so the acquisition related fields are empty. |
| Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2019 |
00121119000 |
Sodium Citrate and Citric Acid Oral Solution 3000/2004mg 30 mL |
02/01/2019 |
74.94 |
323.05 |
None |
Non-innovator Multiple Source Drug |
3098 |
None |
to remain competitive as determined by our pricing committee |
None |
No change or Improvement to product. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Per email where the listed WAC price change dates do not match Medi-Span price change dates. The dates listed in this report are the dates that the WAC price was changed in our ERP system and customers were charged the new WAC price.
The drug was not acquired so the acquisition related fields are empty. |
| Rx0000289 |
Piramal Critical Care |
09/30/2019 |
66794020641 |
Ampicillin / Sulbactam For Inj USP 1.5 G |
09/20/2019 |
12.50 |
65.00 |
None |
Non-innovator Multiple Source Drug |
9127 |
None |
Change in market & cost conditions |
None |
No change or improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code ?127681 (c), Piramal is limiting its response to that which is otherwise in the public domain or publicly available. With respect to Patent Expiration Date, this is a generic drug product and this does not apply. This product was not acquired; however, Piramal distributes on a non-exclusive basis. Piramal does not believe this information is publicly available and has not released this information in the public domain. Piramal does not believe this information is publicly available and has not released this information in the public domain. |
| Rx0000289 |
Piramal Critical Care |
03/31/2019 |
66794064902 |
Levothyroxine Sod for Inj 100mcg/vial |
01/18/2019 |
24.95 |
124.70 |
None |
Innovator Multiple Source Drug |
24261 |
None |
Change in market conditions |
None |
No change or improvement in the drug product |
None |
01/18/2018 |
Fera Pharmaceuticals LLC and Oakwood Laboratories LLC |
None |
1 |
None |
99.75 |
None |
2018 |
99.75 |
None |
Pursuant to CA Health & Safety Code ?127681 (c), Piramal is limiting its response to that which is otherwise in the public domain or publicly available. With respect to Patent Expiration Date, this is a generic drug product and this does not apply. Piramal acquired rights to this product from Fera Pharmaceuticals and Oakwood Laboratories on January 18, 2018. Piramal does not believe this information is publicly available and has not released this information in the public domain. WAC information from Fera/Oakwood was not available; therefore, based on information provided and confirmed by the State of California, Piramal has inserted $99.75 in column 19 WAC at Acquisition and column 22 WAC at Introduction. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011075104 |
BUTRANS 10MCG/HOUR TDS 4S |
01/02/2019 |
38.25 |
440.93 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011075804 |
BUTRANS 15 MCG/HOUR TDS 4S |
01/02/2019 |
55.18 |
636.04 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011075204 |
BUTRANS 20MCG/HOUR TDS 4S |
01/02/2019 |
67.72 |
780.60 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011075004 |
BUTRANS 5 MCG/HOUR TDS 4S |
01/02/2019 |
25.50 |
293.95 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011075704 |
BUTRANS 7.5 MCG/HOUR TDS 4S |
01/02/2019 |
35.69 |
411.52 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011027660 |
HYSINGLA ER 100MG TABLETS 60S |
01/02/2019 |
229.67 |
2647.30 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011027760 |
HYSINGLA ER 120MG TABLETS 60S |
01/02/2019 |
254.52 |
2933.69 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011027160 |
HYSINGLA ER 20MG TABLETS 60S |
01/02/2019 |
49.17 |
566.73 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011027260 |
HYSINGLA ER 30MG TABLETS 60S |
01/02/2019 |
71.77 |
827.23 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011027360 |
HYSINGLA ER 40MG TABLETS 60S |
01/02/2019 |
96.69 |
1114.47 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011027460 |
HYSINGLA ER 60MG TABLETS 60S |
01/02/2019 |
133.88 |
1543.18 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011027560 |
HYSINGLA ER 80MG TABLETS 60S |
01/02/2019 |
180.51 |
2080.58 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011041010 |
OXYCONTIN 10MG TABLETS 100S |
01/02/2019 |
34.92 |
402.46 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011041020 |
OXYCONTIN 10MG TABLETS HUD 20S |
01/02/2019 |
7.17 |
82.64 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011041510 |
OXYCONTIN 15MG TABLETS 100S |
01/02/2019 |
51.40 |
592.49 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011041520 |
OXYCONTIN 15MG TABLETS HUD 20S |
01/02/2019 |
10.55 |
121.56 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011042010 |
OXYCONTIN 20MG TABLETS 100S |
01/02/2019 |
65.12 |
750.57 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011042020 |
OXYCONTIN 20MG TABLETS HUD 20S |
01/02/2019 |
13.36 |
153.96 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011043010 |
OXYCONTIN 30MG TABLETS 100S |
01/02/2019 |
90.56 |
1043.86 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011043020 |
OXYCONTIN 30MG TABLETS HUD 20S |
01/02/2019 |
18.58 |
214.17 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011044010 |
OXYCONTIN 40MG TABLETS 100S |
01/02/2019 |
111.52 |
1285.43 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011044020 |
OXYCONTIN 40MG TABLETS HUD 20S |
01/02/2019 |
22.87 |
263.57 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011046010 |
OXYCONTIN 60MG TABLETS 100S |
01/02/2019 |
157.90 |
1819.96 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011046020 |
OXYCONTIN 60MG TABLETS HUD 20S |
01/02/2019 |
32.39 |
373.38 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011048010 |
OXYCONTIN 80MG TABLETS 100S |
01/02/2019 |
194.60 |
2243.03 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2019 |
59011048020 |
OXYCONTIN 80MG TABLETS HUD 20S |
01/02/2019 |
39.92 |
460.12 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |